Xanthohumol (Prenylflavonoid · Anti-inflammatory · Metabolic Health)

Compound	Xanthohumol
Chemical class	Polyphenol — Prenylflavonoid (Prenylchalcone)
CAS	6754-58-1
Primary source	Humulus lupulus (hop female inflorescences / strobiles)
Key applications	Anti-inflammatory, metabolic, antiproliferative
Claim strength	Moderate
Typical form	Hops extract standardised to xanthohumol
Buy from Herbuno	Hops Flower Extract Powder - Humulus lupulus →

Name origin: From xantho (Greek: yellow) + humulus (genus name), reflecting the yellow pigmentation xanthohumol imparts to hop resin. It is the principal prenylchalcone of hops, present primarily in the lupulin glands of hop strobiles. Traditional use: Hops (Humulus lupulus) have been used in brewing for over 1,000 years and in phytomedicine for sedative, anti-inflammatory, and menopausal applications. Xanthohumol was not historically isolated; the prenylchalcone fraction is responsible for hops’ non-sedative bioactivities (sedative activity is attributed to 2-methyl-3-buten-2-ol from hop degradation). Research trajectory: Xanthohumol has attracted significant research interest for anti-inflammatory, anti-obesity (AMPK), antiproliferative, and antiviral mechanisms. Small human pilot studies are emerging. Commercial source: Xanthohumol is commercially available as a key co-constituent of hops (Humulus lupulus) flower extract; concentrated xanthohumol preparations (up to 40%) are available from specialist botanical suppliers. See sourcing options below.

---

Evidence for Xanthohumol Applications

Anti-inflammatory and NF-κB suppression: Xanthohumol is a potent NF-κB inhibitor at low micromolar concentrations, with documented suppression of COX-2, TNF-α, and IL-6 across macrophage, epithelial, and endothelial models. The prenyl group is considered key to its membrane permeability and intracellular target access. In vivo anti-inflammatory efficacy in rodent models of colitis, liver injury, and obesity-related inflammation is well-documented. Claim strength: Moderate.

Metabolic health and AMPK activation: Xanthohumol activates AMPK and suppresses adipogenesis, reduces hepatic lipid accumulation, and improves insulin sensitivity in diet-induced obesity animal models. A small human pilot study showed modest improvements in metabolic markers in overweight individuals. Relevant for metabolic syndrome formulations. Claim strength: Moderate (strong preclinical; emerging human).

Antiproliferative activity: Xanthohumol demonstrates broad antiproliferative activity across multiple cancer cell lines via NF-κB inhibition, apoptosis induction, and cell cycle arrest. Preclinical evidence is substantial; clinical translation is in early stages. Not appropriate for supplement therapeutic cancer claims but relevant to research-audience communication. Claim strength: Moderate (preclinical).

---

Dosage & Formulator Specification

No established human clinical dose for xanthohumol. Animal metabolic studies typically use 30–60 mg/kg/day; human equivalent dose (by body surface area scaling) would be approximately 5–10 mg/kg, suggesting 350–700 mg/day xanthohumol for a 70 kg adult — substantially more than standard hops extract delivers. This discrepancy between animal dose and commercially practical supplement dose is a key limitation for metabolic applications.

Commercial hops extracts typically contain 0.1–0.5% xanthohumol by weight. At 200 mg/day hops extract (0.3% xanthohumol), actual xanthohumol delivery is ~0.6 mg — far below animal study effective doses. Concentrated xanthohumol isolates (≥80% HPLC) are available from specialist suppliers for higher-dose applications.

Xanthohumol has low aqueous solubility and high lipophilicity (logP ~4). Lipid-based delivery or cyclodextrin complexation is recommended. It readily converts to the isoflavone 8-prenylnaringenin (8-PN) upon heating or under acidic conditions — both relevant to processing and formulation stability.

---

Frequently Asked Questions — Xanthohumol

Does xanthohumol in hops explain beer’s health associations?
Only partially. Beer contains very low xanthohumol concentrations (typically 0.15–0.2 mg/L), as most xanthohumol converts to isoxanthohumol (a related but less bioactive compound) during brewing. The cardiovascular associations of moderate beer consumption are attributed to multiple factors. Concentrated hops extracts standardised to xanthohumol content are necessary for supplement-relevant xanthohumol exposure.

What is the relationship between xanthohumol and 8-prenylnaringenin?
Xanthohumol (a chalcone) cyclises to isoxanthohumol (a flavanone) under heat or acid conditions during brewing. Isoxanthohumol is then metabolised by gut microbiota to 8-prenylnaringenin (8-PN), the most potent phytoestrogenic compound known. Xanthohumol itself has minimal direct estrogenic activity; its estrogenic potential is primarily via this metabolic conversion pathway in vivo.

Should xanthohumol products carry a phytoestrogen advisory?
Xanthohumol itself has low direct estrogenic activity. However, given its in vivo conversion to 8-prenylnaringenin (a potent phytoestrogen), prudent formulation practice includes an advisory for hormone-sensitive populations — particularly for high-dose concentrated xanthohumol products. Standard hops extracts at typical supplement doses present minimal estrogenic concern.

Is there a bioavailability issue with xanthohumol supplementation?
Yes. Xanthohumol has poor oral bioavailability due to low aqueous solubility, phase II conjugation (glucuronidation/sulfation), and conversion to isoxanthohumol and 8-PN in the GI tract. Bioavailability-enhanced formulations (nanoparticles, cyclodextrin complexes, liposomes) significantly improve plasma xanthohumol concentrations in animal studies. This is an active area of formulation research.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery